Literature DB >> 180809

The effects of dipivalyl epinephrine on the eye.

M B Kaback, S M Podos, T S Harbin, A Mandell, B Becker.   

Abstract

We treated one eye each of ten patients with ocular hypertension with dipivalyl epinephrine (DPE), a congener of epinephrine. Pupil size and intraocular pressure were measured before and at intervals up to 240 minutes after instillation of a single drop of DPE in concentrations from 0.005 to 0.5%. Concentrations of 0.025% DPE and greater significantly reduced IOP, and mydriasis was induced by concentrations of 0.1% DPE or greater. Comcentrations of 0.1% DPE, instilled twice daily for one month, significantly reduced intraocular pressure during diurnal testing on days 2 and 31. No toxic side effects were noted. The DPE produced dose-related increases of cyclic adenosine monophosphate in the aqueous humor of rabbits.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 180809     DOI: 10.1016/0002-9394(76)90360-3

Source DB:  PubMed          Journal:  Am J Ophthalmol        ISSN: 0002-9394            Impact factor:   5.258


  10 in total

Review 1.  Pharmacological therapy for glaucoma: a review.

Authors:  P F Hoyng; L M van Beek
Journal:  Drugs       Date:  2000-03       Impact factor: 9.546

2.  Beta-blockers in the treatment of chronic simple glaucoma.

Authors:  R A Hitchings
Journal:  Br Med J (Clin Res Ed)       Date:  1982-07-10

3.  The dose-response relationships of dipivalyl epinephrine in open-angle glaucoma.

Authors:  G K Krieglstein; W Leydhecker
Journal:  Albrecht Von Graefes Arch Klin Exp Ophthalmol       Date:  1978-02-22

4.  Assessment of bronchial effects following topical administration of butylamino-phenoxy-propanol-acetate, an oculoselective beta-adrenoceptor blocker in asthmatic subjects.

Authors:  K G Bauer; F Brunner-Ferber; L M Distlerath; E A Lippa; B Binkowitz; P Till; G A Kaik
Journal:  Br J Clin Pharmacol       Date:  1992-08       Impact factor: 4.335

5.  The importance of eyelid closure and nasolacrimal occlusion following the ocular instillation of topical glaucoma medications, and the need for the universal inclusion of one of these techniques in all patient treatments and clinical studies.

Authors:  Allan J Flach
Journal:  Trans Am Ophthalmol Soc       Date:  2008

6.  A single-blind randomised trial comparing adrenaline 1.0% with dipivalyl epinephrine (propine) 0.1% in the treatment of open-angle glaucoma and ocular hypertension.

Authors:  K B Mills; N A Jacobs
Journal:  Br J Ophthalmol       Date:  1988-06       Impact factor: 4.638

7.  Effects of adrenergic drugs on aqueous cAMP and cGMP and intraocular pressure.

Authors:  J M Rowland; D E Potter
Journal:  Albrecht Von Graefes Arch Klin Exp Ophthalmol       Date:  1979

8.  Cardiovascular effects of epinephrine and dipivalyl epinephrine applied topically to the eye in patients with glaucoma.

Authors:  C R Kerr; I Hass; S M Drance; M B Walters; M Schulzer
Journal:  Br J Ophthalmol       Date:  1982-02       Impact factor: 4.638

9.  Bidirectional Modulation of Alcohol-Associated Memory Reconsolidation through Manipulation of Adrenergic Signaling.

Authors:  Moritz J W Schramm; Barry J Everitt; Amy L Milton
Journal:  Neuropsychopharmacology       Date:  2015-08-17       Impact factor: 7.853

10.  Glaucoma alters the circadian timing system.

Authors:  Elise Drouyer; Ouria Dkhissi-Benyahya; Christophe Chiquet; Elizabeth WoldeMussie; Guadalupe Ruiz; Larry A Wheeler; Philippe Denis; Howard M Cooper
Journal:  PLoS One       Date:  2008-12-12       Impact factor: 3.240

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.